Introduction Poor aqueous solubility of small molecular drug candidates constitutes an increasing challenge in drug development
1135935 Abstract The objective of this study was to utilize physiologically relevant dynamic dissolution testing with the TNO intestinal
Our findings demonstrate the differential bioavailability of celecoxib between normal and polyp tissues and its potential effects on clinical response in patients with FAP
Beta-casein (bCN) micelles were developed as a platform for improved oral bioavailability (BA) of poorly water-soluble drugs
Bioavailability of Celecoxib Formulated with Mesoporous Magnesium Carbonate—An In Vivo Evaluation by Teresa Zardán Gómez de la Torre 1,*, Tuulikki
We found that celecoxib bioavailability was reduced in colorectal polyps
Celecoxib (CXB) is a Biopharmaceutical Classification System (BCS) Class II molecule with high permeability that is practically insoluble in water
Here we demonstrate a proof-of-concept using the NSAID celecoxib (Cx) loaded into bCN micelles (Cx/bCN)
It is evenly distributed in vivo and has a volume of distribution of 455 ± 166 L in humans ( 5 )
The two celecoxib formulations were orally administrated in male rats (average of n = 6 animals per group), and blood samples for plasma were taken from all animals at
Long chain systems displayed higher celecoxib bioavailability than equivalent medium chain systems, both at supersaturated and non-supersaturated drug loads
As long term use of celecoxib may affect renal function, and urinary Celecoxib (CLX), a selective COX-2 inhibitor, is a biopharmaceutics classification system (BCS) class II drug with its bioavailability being limited by thepoor aqueoussolubility
Methods: Amorphous drug/polymer nanoparticles containing celecoxib were prepared using ethyl cellulose and either sodium caseinate or bile salt
To improve the solubility and bioavailability and to get faster onset of action of celecoxib, the self-microemulsifying drug delivery system (SMEDDS) was developed
T o the best of our knowledge, this is the first
126 Almansa et al 127 identified CTC and investigated dissolution properties of the cocrystal
Pharmacologi-cally, CLX is a specific COX-2 inhibitor used to treat pain and inflammation [14]
Solid dispersion shows a reduction in particle size and an increase in surface area of poorly water-soluble